NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have increased by 4.3% and is now trading at $82.68.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings data on Friday, July, 31st. The company reported $1.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.23. The business had revenue of $10.87 billion for the quarter, compared to analysts' expectations of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The company's revenue for the quarter was down 7.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.30 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. declared a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. declared that its board has authorized a share repurchase program on Thursday, October 25th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its shares are undervalued.

Merck & Co., Inc. updated its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 analysts have issued 1-year price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.93 in the next twelve months. This suggests a possible upside of 14.8% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

News headlines about MRK stock have trended negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.25%), Nordea Investment Management AB (0.73%), FMR LLC (0.51%), Sumitomo Mitsui Trust Holdings Inc. (0.50%), Macquarie Group Ltd. (0.46%) and Swiss National Bank (0.43%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Marshall Wace North America L.P., Toronto Dominion Bank, Bank of Nova Scotia, Thornburg Investment Management Inc., CIBC Private Wealth Group LLC, Victory Capital Management Inc., and Bank of Montreal Can. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Sarasin & Partners LLP, Epoch Investment Partners Inc., Ceredex Value Advisors LLC, TD Asset Management Inc., Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, and Federated Hermes Inc..
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.68.

Merck & Co., Inc. has a market capitalization of $209.12 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]